Novo Nordisk Shares Climb on UK Wegovy Pill Approval
Novo Nordisk shares gained momentum today following regulatory clearance from UK authorities for its oral version of the weight-loss drug, Wegovy. This milestone marks a strategic shift for the pharmaceutical giant as it seeks to capture a larger share of the obesity treatment market. By diversifying its delivery methods beyond injections, Novo Nordisk strengthens its competitive position against rivals, signaling robust growth potential for investors monitoring the firm’s long-term product pipeline.